First FDA-Cleared Alzheimer's Blood Test Has Limited Real-World Validation

The first FDA-cleared blood test for Alzheimer's (Lumipulse G p-tau217/Aβ1-42 ratio, May 2025) achieves 91.7% concordance with amyloid PET scans. But it's only cleared for symptomatic patients 55+, and real-world performance in diverse populations, primary care settings, and early pre-symptomatic stages remains unclear.

Plasma p-tau217 detected AD pathology with AUC of 0.93-0.96. In secondary care, accuracy was 89-91%, positive predictive value 89-95%, negative predictive value 77-90%. A 2025 Nature Medicine study validated p-tau217 on a fully automated platform across primary and secondary care. However, serum p-tau217 concentrations differed across platforms, requiring different disease-specific cutoffs. Early evidence suggests p-tau217 could serve as a clinical trial endpoint for anti-amyloid therapies. Real-world deployment challenges include standardization across labs and performance in underrepresented populations.

Why It Matters

6.2M Americans have Alzheimer's, projected to reach 12.7M by 2050. Current gold standard (amyloid PET) costs $5,000-8,000 per scan. A reliable blood test could reduce diagnostic costs 90%+ and enable screening at scale. Critical for determining eligibility for new anti-amyloid therapies (lecanemab, donanemab).

Startup Approach

Develop point-of-care Alzheimer's blood test that works in primary care (not just reference labs). Combine p-tau217 with additional biomarkers (GFAP, NfL) for improved staging accuracy. Build clinical decision support tools that integrate blood biomarker results with cognitive assessments and genetic risk.

NIH Funding

NIA funds blood biomarker research extensively. ADNI (Alzheimer's Disease Neuroimaging Initiative) validates biomarkers. NIH budget for Alzheimer's: $3.7B/year.

Who's Working On It

Fujirebio (Lumipulse G platform, FDA cleared), C2N Diagnostics (PrecivityAD), Roche Diagnostics (Elecsys p-tau217), ALZpath (Simoa-based assays), Quanterix (Simoa HD-X platform)